UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
Position in AMLX — Amylyx Pharmaceuticals, Inc.
CIK 861177
NEW YORK, NY
Position in AMLX
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$2,183,535
+$989,573 QoQ
Shares Held
157,089
+58.9% QoQ
Ownership
0.141%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
5 quarters on record
Voting authority
Sole 40%
Shared 0%
None 60%
Common Shares in AMLX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $926,551,772 across 34 Drug Manufacturers - Specialty & Generic names. AMLX ranks #19 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
4,398,351 | $519,929,066 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
207,309 | $122,930,085 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
571,719 | $75,318,257 | |
| 4 | VTRS |
Viatris Inc
|
3,964,630 | $53,562,146 | |
| 5 | LNTH |
Lantheus Holdings, Inc.
|
486,498 | $36,900,870 | |
| 6 | ELAN |
Elanco Animal Health Inc
|
1,526,922 | $36,539,240 | |
| 7 | ALKS |
Alkermes plc.
|
403,153 | $14,255,486 | |
| 8 | HIMS |
Hims & Hers Health, Inc.
|
443,527 | $9,207,616 |
All Filings in AMLX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,183,535 | 157,089 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $1,193,962 | 98,838 | Shares | Defined | 2026-02-13 | |
| 2024-03-31 | $55,948 | 19,700 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $289,984 | 19,700 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $509,018 | 27,800 | Shares | Sole | 2023-11-13 | |
| No filing history on record for this holder in this stock. | ||||||